Events
- July 6 - 11, 2008
Poster Presentation at a Gordon Research Conference
- May 21, 2008
Lloyd Segal, Thallion’s CEO, speaks about the future of the Canadian biotech sector on the Business News Network.
- April 12 - 16, 2008
Poster Presentations at the 2008 AACR Conference
News
- June 26, 2008
Thallion receives health canada approval to initiate Phase II study for TLN-232 in metastatic melanoma patients- Company initiates Phase II study with its second oncology product -
- May 12, 2008
Thallion Receives Health Canada Approval to Initiate Phase II for TLN-4601 in Brain Cancer
- April 8, 2008
Thallion Announces 2008 First Quarter Results